These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 28502040)
1. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040 [TBL] [Abstract][Full Text] [Related]
2. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035 [TBL] [Abstract][Full Text] [Related]
3. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639 [TBL] [Abstract][Full Text] [Related]
4. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720 [TBL] [Abstract][Full Text] [Related]
5. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L Med Oncol; 2013; 30(3):604. PubMed ID: 23686699 [TBL] [Abstract][Full Text] [Related]
6. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L Med Oncol; 2013; 30(3):630. PubMed ID: 23783485 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280 [TBL] [Abstract][Full Text] [Related]
8. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432 [TBL] [Abstract][Full Text] [Related]
9. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Liu X; Cheng D; Kuang Q; Liu G; Xu W Pharmacogenomics J; 2014 Apr; 14(2):120-9. PubMed ID: 23529007 [TBL] [Abstract][Full Text] [Related]
10. Insights, challenges, and future directions in irinogenetics. Kim TW; Innocenti F Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881 [TBL] [Abstract][Full Text] [Related]
11. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132 [TBL] [Abstract][Full Text] [Related]
12. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344 [TBL] [Abstract][Full Text] [Related]
14. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078 [TBL] [Abstract][Full Text] [Related]
15. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
16. Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. Hirasawa A; Zama T; Akahane T; Nomura H; Kataoka F; Saito K; Okubo K; Tominaga E; Makita K; Susumu N; Kosaki K; Tanigawara Y; Aoki D J Hum Genet; 2013 Dec; 58(12):794-8. PubMed ID: 24088669 [TBL] [Abstract][Full Text] [Related]
17. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. Biason P; Masier S; Toffoli G J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239 [TBL] [Abstract][Full Text] [Related]
18. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Li H; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276 [TBL] [Abstract][Full Text] [Related]
19. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581 [TBL] [Abstract][Full Text] [Related]
20. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients. Peng H; Duan Z; Pan D; Wen J; Wei X Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]